A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer

Clinical Cancer Research

Volumn 19, Issue 11, 2013, Pages 3068-3077

  Socinski, Mark A ^a   Goldman, Jonathan ^c   El Hariry, Iman ^e   Koczywas, Marianna ^d   Vukovic, Vojo ^e   Horn, Leora ⁱ   Paschold, Eugene ^j   Salgia, Ravi ^k   West, Howard ^m   Sequist, Lecia V ^f   Bonomi, Philip ^l   Brahmer, Julie ⁿ   Chen, Lin Chi ^o   Sandler, Alan ^p   Belani, Chandra P ^b   Webb, Timothy ^q   Harper, Harry ^r   Huberman, Mark ^g   Ramalingam, Suresh ^s   Wong, Kwok Kin ^h   Filovici, Florentina Teo ^e   Guo, Wei ^e   Shapiro, Geoffrey I ^h   more..

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b PENN STATE CANCER INSTITUTE   (United States)

^c Premiere Oncology   (United States)

^d CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^e Synta Pharmaceuticals Corp   (United States)

^f MASSACHUSETTS GENERAL HOSPITAL   (United States)

^g BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^h DANA FARBER CANCER INSTITUTE   (United States)

ⁱ VANDERBILT INGRAM CANCER CENTER   (United States)

^j PA   (United States)

^k UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^l RUSH UNIVERSITY MEDICAL CENTER   (United States)

^m Swedish Cancer Institute   (United States)

ⁿ JOHNS HOPKINS UNIVERSITY   (United States)

^o NEVADA CANCER INSTITUTE   (United States)

^p OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^q Genesis Cancer Center   (United States)

^r HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

^s EMORY UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; BEVACIZUMAB; CARBOPLATIN; CELECOXIB; CISPLATIN; CRIZOTINIB; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GANETESPIB; GEMCITABINE; MUTANT PROTEIN; NAVELBINE; PACLITAXEL; PEMETREXED; PLACEBO; SELUMETINIB; SUNITINIB; UNCLASSIFIED DRUG; XYTOTAX;

ADULT; ADVANCED CANCER; AGED; ALK GENE; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHENIA; COHORT ANALYSIS; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EGFR GENE; FATIGUE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE MUTATION; GENE REARRANGEMENT; GENOTYPE; HEART ARREST; HEART ATRIUM FIBRILLATION; HEMOPTYSIS; HUMAN; HYPERBILIRUBINEMIA; KIDNEY FAILURE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; NAUSEA; ONCOGENE K RAS; OPEN STUDY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SIDE EFFECT; TREATMENT DURATION; TREATMENT RESPONSE; VISUAL DISORDER; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; GENE REARRANGEMENT; GENOTYPE; HSP90 HEAT-SHOCK PROTEINS; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; RECEPTOR PROTEIN-TYROSINE KINASES; TREATMENT OUTCOME; TRIAZOLES;

EID: 84878971581     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-3381     Document Type: Article

References (49)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics. CA Cancer J Clin 2012;62:10-29.
2. Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008;26:3543-51.
3. D'Addario G, Pintilie M, Leighl NB, Feld R, Cernyl T, Shepherd FA. Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of the published literature. J Clin Oncol 2005;23:2926-36. (Pubitemid 46224111)
4. West L, Vidwans SJ, Campbell NP, Shrager J, Simon GR, Bueno R, et al. A novel classification of lung cancer into molecular subtypes. PLoS One 2012;7:e31906.
5. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007;448:561-6. (Pubitemid 47206930)
6. Wang Y, Schmid-Bindert G, Zhou C. Erlotinib in the treatment of advanced non-small cell lung cancer: an update for clinicians. Ther Adv Med Oncol 2012;4:19-29.
7. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010;363:1693-703.
8. Shaw AT, Yeap BY, Solomon BJ, Riely GJ, Gainor J, Engelman JA, et al. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol 2011;12:1004-12.
9. Curran MP. Crizotinib: In locally advanced or metastatic non-small cell lung cancer. Drugs 2012;72:99-107.
10. Shimamura T, Shapiro GI. Heat shock protein 90 inhibition in lung cancer. J Thorac Oncol 2008;3:S152-9 (Pubitemid 351786749)
11. Shimamura T, Lowell AM, Engelman JA, Sahpiro GI. Epidermal growth factor receptors harboring kinase domain mutations associate with the heat shock protein 90 chaperone and are destabilized following exposure to geldanamycins. Cancer Res 2005;65:6401-8. (Pubitemid 40994428)
12. Schulte TW, Blagosklonny MV, Ingui C, Neckers L. Disruption of the Raf-1-Hsp90 molecular complex results in destabilization of Raf-1 and loss of Raf-1-Ras association. J Biol Chem 1995;270:24585-8.
13. da Rocha Dias S, Friedlos F, Light Y, Springer C, Workman P, Marais R. Activated B-RAF is an Hsp90 client protein that is targeted by the anticancer drug 17-allylamino-17-demethoxygeldanamycin. Cancer Res 2005;65:10686-91.
14. Grbovic OM, Basso AD, Sawai A, Ye Q, Friedlander P, Solit D, et al. V600E B-Raf requires the Hsp90 chaperone for stability and is degraded in response to Hsp90 inhibitors. Proc Natl Acad Sci U S A 2006;103:57-62. (Pubitemid 43076104)
15. Zheng FF, Kuduk SD, Chiosis G, Müunster PN, Sepp-Lorenzino L, Danishefsky SJ, et al. Identification of a geldanamycin dimer that induces the selective degradation of HER-family tyrosine kinases. Cancer Res 2000;60:2090-4. (Pubitemid 30225164)
16. Xu W, Soga S, Beebe K, Lee MJ, Kim YS, Trepel J, et al. Sensitivity of epidermal growth factor receptor and ErbB2 exon 20 insertion mutants to Hsp90 inhibition. Br J Cancer 2007;97:741-4. (Pubitemid 47396295)
17. Chen Z, Sasaki T, Tan X, Carretero J, Shimamura T, Li D, et al. Inhibition of ALK, PI3K/MEK, and HSP90 in murine lung adenocarcinoma induced by EML4-ALK fusion oncogene. Cancer Res 2010;70:9827-36.
18. Normant E, Paez G, West KA, Lim AR, Slocum KL, Tunkey C, et al. The Hsp90 inhibitor IPI-504 rapidly lowers EML4-ALK levels and induces tumor regression in ALK-driven NSCLC models. Oncogene 2011;30:2581-6.
19. Neckers L. HSP90 and cancer: Targeting a dynamic chaperone complex. Annals Oncol 2010;21:ii23.
20. Shimamura T, Li D, Ji H, Haringsma HJ, Liniker E, Borgman CL, et al. Hsp90 inhibition suppresses mutant EGFR-T790M signaling and overcomes kinase inhibitor resistance. Cancer Res 2008;68:5827-38.
21. Regales L, Balak MN, Gong Y, Politi K, Sawai A, Le C, et al. Development of new mouse lung tumor models expressing EGFR T790M mutants associated with clinical resistance to kinase inhibitors. PLoS One 2007;2:e810.
22. Katayama R, Khan TM, Benes C, Lifshits E, Ebi H, Rivera VM, et al. Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK. Proc Natl Acad Sci U S A 2011;108:7535-40.
23. Sos ML, Michel K, Zander T, Weiss J, Frommolt P, Peifer M, et al. Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions. J Clin Invest 2009;119:1727-40.
24. Blasco RB, Francoz S, Santamaria D, Canamero M, Dubus P, Charron J, et al. c-Raf, but not B-Raf, is essential for development of K-Ras oncogene-driven non-small cell lung carcinoma. Cancer Cell 2011;19:652-63.
25. Sequist LV, Gettinger S, Senzer NN, Martins RG, Jäanne PA, Lilenbaum R, et al. Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer. J Clin Oncol 2010;28:1-10.
26. Ying W, Du Z, Sun L, Foley KP, Proia DA, Blackman RK, et al. Ganetespib, a unique triazolone-containing Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapy. Mol Cancer Ther 2012;11:475-84.
27. Wang Y, Trepel JB, Neckers LM, Giaccone G. STA-9090, a small-molecule Hsp90 inhibitor for the potential treatment of cancer. Curr Opin Invest Drugs 2010;11:1466-76.
28. Proia DA, Foley KP, Korbut T, Sang J, Smith D, Bates RC, et al. Multifaceted intervention by the Hsp90 inhibitor ganetespib (STA-9090) in cancer cells with activated JAK/STAT signaling. PLoS One 2011;6:e18552.
29. He S, Zhang C, Shafi AA, Sequeira M, Acquaviva J, Friedland JC, et al. Potent activity of the hsp90 inhibitor ganetespib in prostate cancer cells irrespective of androgen receptor status or variant receptor expression. Int J Oncol 2013;42:35-43.
30. Choi HK, Lee K. Recent updates on the development of ganetespib as a Hsp90 inhibitor. Arch Pharm Res 2012;35:1855-9.
31. National Cancer Institute. Common Terminology Criteria for Adverse Events v4.0 (CTCAE). Bethesda, MD: US Department of Health And Human Services, National Institutes of Health v4.03; 2010.
32. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-47.
33. Soria JC, Massard C, Le Chevalier T. Should progression-free survival be the primary measure of efficacy for advanced NSCLC therapy? Ann Oncol 2010;21:2324-32.
34. Sasaki T, Koivunen J, Ogino A, Yanagita M, Nikiforow S, Zheng W, et al. A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. Cancer Res 2011;71:6051-60.
35. Allouche M. ALK is a novel dependence receptor: potential implications in development and cancer. Cell Cycle 2007;6:1533-8. (Pubitemid 47327936)
36. Christensen JG, Zou HY, Arango ME, Li Q, Lee JH, McDonnell SR, et al. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Mol Cancer Ther 2007;6:3314-22.
37. Sakamoto H, Tsukaguchi T, Hiroshima S, Kodama T, Kobayashi T, Fukami TA, et al. CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant. Cancer Cell 2011;19:679.
38. Katayama R, Shaw AT, Khan TM, Mino-Kenudson M, Solomon BJ, Halmos B, et al. Mechanisms of acquired crizotinib resistance in ALK rearranged lung cancers. Sci Transl Med 2012;4:120ra17.
39. Shaw AT, Solomon B, Kenudson MM. Crizotinib and testing for ALK. J Natl Compr Cancer Netw 2011;9:1135-41.
40. Mino-Kenudson M, Chirieac LR, Law K, Hornick JL, Lindeman N, Mark EJ, et al. A novel, highly sensitive antibody allows for routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry. Clin Cancer Res 2010;16:1561-71
41. Wallender ML, Geiersbach KB, Tripp SR, Layfield LJ. Comparison of reverse transcription-polymerase chain reaction, immunohistochemistry, and fluorescence in situ hybridization methodologies for detection of echinoderm microtubule-associated proteinlike 4-anaplastic lymphoma kinase fusion-positive non-small cell lung carcinoma. Arch Pathol Lab Med 2012;136:796-803.
42. Heuckmann JM, Balke-Want H, Malchers F, Peifer M, Sos ML, Koker M, et al. Differential protein stability and ALK inhibitor sensitivity of EML4-ALK fusion variants. Clin Cancer Res 2012;18:4682-90.
43. Sequist LV, Waltman BA, Dias-Santagata D, Digumarthy S, Turke AB, Fidias P, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Trans Med 2011;3:75ra26.
44. Shimamura T, Perera SA, Foley KP, Sang J, Rodig SJ, Inoue T, et al. Ganetespib (STA-9090), a nongeldanamycin HSP90 inhibitor, has potent antitumor activity in in vitro and in vivo models of non-small cell lung cancer. Clin Cancer Res 2012;18:4973-85.
45. Pratt WB, Morishima Y, Peng HM, Osawa Y. Proposal for a role of the Hsp90/Hsp70-based chaperone machinery in making triage decisions when proteins undergo oxidative and toxic damage. Exp Biol Med 2010;235:278-89.
46. Fukuyo Y, Inoue M, Nakajima T, Higashikubo R, Horikoshi NT, Hunt C, et al. Oxidative stress plays a critical role in inactivating mutant BRAF by geldanamycin derivatives. Cancer Res 2008;68:6324-30.
47. De Raedt T, Walton Z, Yecies JL, Li D, Chen Y, Malone CF, et al. Exploiting cancer cell vulnerabilities to develop a combination therapy for ras-driven tumors. Cancer Cell 2011;20:400-13.
48. Jhaveri K, Taldone T, Modi S, Chiosis G. Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers. Biochim Biophys Acta 2011;1823:742-55.
49. Suzuki A, Sekiya S, Gunshima E, Fujii S, Taniguchi H. EGF signaling activates proliferation and blocks apoptosis of mouse and human intestinal stem/progenitor cells in long term monolayer cell culture. Lab Invest 2010;90:1425-36.